|  Help  |  About  |  Contact Us

Publication : CCAAT/enhancer binding protein δ is a transcriptional repressor of α-synuclein.

First Author  Valente T Year  2020
Journal  Cell Death Differ Volume  27
Issue  2 Pages  509-524
PubMed ID  31209363 Mgi Jnum  J:302987
Mgi Id  MGI:6510146 Doi  10.1038/s41418-019-0368-8
Citation  Valente T, et al. (2020) CCAAT/enhancer binding protein delta is a transcriptional repressor of alpha-synuclein. Cell Death Differ 27(2):509-524
abstractText  alpha-Synuclein is the main component of Lewy bodies, the intracellular protein aggregates representing the histological hallmark of Parkinson's disease. Elevated alpha-synuclein levels and mutations in SNCA gene are associated with increased risk for Parkinson's disease. Despite this, little is known about the molecular mechanisms regulating SNCA transcription. CCAAT/enhancer binding protein (C/EBP) beta and delta are b-zip transcription factors that play distinct roles in neurons and glial cells. C/EBPbeta overexpression increases SNCA expression in neuroblastoma cells and putative C/EBPbeta and delta binding sites are present in the SNCA genomic region suggesting that these proteins could regulate SNCA transcription. Based on these premises, the goal of this study was to determine if C/EBPbeta and delta regulate the expression of SNCA. We first observed that alpha-synuclein CNS expression was not affected by C/EBPbeta deficiency but it was markedly increased in C/EBPdelta-deficient mice. This prompted us to characterize further the role of C/EBPdelta in SNCA transcription. C/EBPdelta absence led to the in vivo increase of alpha-synuclein in all brain regions analyzed, both at mRNA and protein level, and in primary neuronal cultures. In agreement with this, CEBPD overexpression in neuroblastoma cells and in primary neuronal cultures markedly reduced SNCA expression. ChIP experiments demonstrated C/EBPdelta binding to the SNCA genomic region of mice and humans and luciferase experiments showed decreased expression of a reporter gene attributable to C/EBPdelta binding to the SNCA promoter. Finally, decreased CEBPD expression was observed in the substantia nigra and in iPSC-derived dopaminergic neurons from Parkinson patients resulting in a significant negative correlation between SNCA and CEBPD levels. This study points to C/EBPdelta as an important repressor of SNCA transcription and suggests that reduced C/EBPdelta neuronal levels could be a pathogenic factor in Parkinson's disease and other synucleinopathies and C/EBPdelta activity a potential pharmacological target for these neurological disorders.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

6 Bio Entities

Trail: Publication

0 Expression